For professionals in the chemical and pharmaceutical industries, a deep understanding of key chemical intermediates is crucial for successful product development and manufacturing. 4,4-Dimethoxy-N,N-dimethyl-1-butanamine, identified by CAS number 19718-92-4, is one such compound, notable for its chemical characteristics and its pivotal role in synthesizing important pharmaceuticals. NINGBO INNO PHARMCHEM CO.,LTD. provides this essential intermediate, ensuring that industries have access to reliable, high-quality material.

The chemical profile of 4,4-Dimethoxy-N,N-dimethyl-1-butanamine is defined by its molecular structure, which includes an acetal group and a tertiary amine. This combination imparts specific reactivity and solubility properties. Typically appearing as a colorless to pale yellow liquid, it is soluble in various organic solvents, facilitating its use in solution-phase reactions. Its boiling point is approximately 164°C, and its density is around 0.892 g/mL. These properties are critical for its handling and application in chemical synthesis. The compound’s stability, particularly its sensitivity to moisture, also dictates specific storage and handling procedures, which are well-understood by NINGBO INNO PHARMCHEM CO.,LTD. to ensure product integrity.

The synthesis of 4,4-Dimethoxy-N,N-dimethyl-1-butanamine is a well-established process, often involving the reaction of suitable precursors under controlled conditions to achieve high purity. While specific proprietary methods may vary, common routes involve the reaction of amines with halogenated acetals or Grignard reagents. The pharmaceutical industry relies heavily on the availability of this intermediate for the production of triptans, drugs used to treat migraines. The efficiency and yield of these synthesis processes are paramount, making the quality of the starting materials like 4,4-Dimethoxy-N,N-dimethyl-1-butanamine a critical factor. NINGBO INNO PHARMCHEM CO.,LTD. plays a vital role in this chain by offering a dependable supply, allowing manufacturers to focus on their production processes. The purchase of this intermediate directly supports the ongoing development and availability of essential medicines.